<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417115</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-100361</org_study_id>
    <secondary_id>Registerplattform OPAL</secondary_id>
    <nct_id>NCT03417115</nct_id>
  </id_info>
  <brief_title>Breast Cancer Registry Platform</brief_title>
  <acronym>OPAL</acronym>
  <official_title>Treatment and Outcome of Patients With Breast Cancer: Clinical Research Platform for Real World Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is to set up a national, prospective, longitudinal, multicenter&#xD;
      cohort study with associated satellites, a tumor registry platform, to document uniform data&#xD;
      on characteristics, molecular diagnostics, treatment and course of disease, to collect&#xD;
      patient-reported outcomes and to establish a decentralized biobank for patients with advanced&#xD;
      breast cancer in Germany.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OPAL is a national, observational, prospective, longitudinal, multicenter cohort study (tumor&#xD;
      registry platform) with the purpose to record information on the antineoplastic treatment of&#xD;
      advanced breast cancer in Germany. The registry will follow patients for up to five years. It&#xD;
      will identify common therapeutic sequences and changes in the treatment of the disease. At&#xD;
      inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous&#xD;
      treatments are collected. During the course of observation data on all systemic treatments,&#xD;
      radiotherapies, surgeries, and outcome are documented.&#xD;
&#xD;
      Health-realted quality of life in patients with advanced breast cancer will be evaluated for&#xD;
      up to five years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2017</start_date>
  <completion_date type="Anticipated">April 2029</completion_date>
  <primary_completion_date type="Anticipated">April 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Treatment reality</measure>
    <time_frame>5 years</time_frame>
    <description>Description of treatment reality (Course of systemic treatments and sequential treatments) applied in German routine practice measured as the frequency of the various systemic treatments applied per line of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response</measure>
    <time_frame>5 years</time_frame>
    <description>Documentation of response rates per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Documentation of progression-free survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Documentation of date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (Patient-reported outcome)</measure>
    <time_frame>3.5 years</time_frame>
    <description>EORTC QLQ-C30 core questionnaire and additional items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Documentation of disease-free survival.</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced breast cancer - Her2 positive</arm_group_label>
    <description>Patients with HER2-positive advanced breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced breast cancer - triple negative</arm_group_label>
    <description>Patients with triple negative advanced breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced breast cancer - HR positive, Her2 negative</arm_group_label>
    <description>Patients with HR positive, Her2 negative advanced breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early breast cancer - HER2 positive</arm_group_label>
    <description>Patients with HER2 positive early breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early breast cancer - triple negative</arm_group_label>
    <description>Patients with triple negative early breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early breast cancer - HR positive, HER2 negative</arm_group_label>
    <description>Patients with HR positive, HER2 negative early breast cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult female and male patients with breast cancer starting first systemic treatment for EBC&#xD;
        or ABC.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        EBC cohort:&#xD;
&#xD;
          -  Female and male patients with early breast cancer (stage I-III defined as breast&#xD;
             cancer that has not spread beyond the breast or the axillary lymph nodes)&#xD;
&#xD;
          -  Patients at the start of their initial systemic treatment for EBC, i.e. at start of&#xD;
             neoadjuvant treatment for patients receiving neoadjuvant thera-py or at start of&#xD;
             adjuvant treatment if no neoadjuvant therapy is given. Treatment can be cytotoxic,&#xD;
             endocrine, or targeted substances, what-ever was given first&#xD;
&#xD;
        ABC cohort:&#xD;
&#xD;
          -  Female and male patients with advanced breast cancer (stage IV de-fined as synchrone&#xD;
             or metachrone diagnosis of distant metastases at inclusion)&#xD;
&#xD;
          -  Patients at the start of their initial first-line systemic treatment for ABC, which&#xD;
             can be cytotoxic, endocrine or targeting a specific signaling pathway, whatever is&#xD;
             given first&#xD;
&#xD;
        All cohorts:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
               -  Patients participating in the PRO module: signing of informed consent form and&#xD;
                  completion of baseline questionnaire before start of initial systemic treatment&#xD;
                  for EBC or systemic first-line treatment for ABC&#xD;
&#xD;
               -  Patients not participating in the PRO module: within six weeks after start of&#xD;
                  initial systemic treatment for EBC or systemic first-line treatment for ABC&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prior systemic therapy (cytotoxic, endocrine, or targeted) for EBC or&#xD;
             ABC&#xD;
&#xD;
          -  Patients who do not receive any systemic therapy for EBC or ABC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Marschner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Praxis für interdisziplinäre Onkologie &amp; Hämatologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Kruggel</last_name>
    <phone>+49 761 15242-0</phone>
    <email>info@iomedico.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Hof</last_name>
    <phone>+49 761 15242-0</phone>
    <email>info@iomedico.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Multiple sites all over germany</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>iOMEDICO AG</last_name>
      <phone>+49 761 15242-0</phone>
      <email>info@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Registry</keyword>
  <keyword>Health Services Research</keyword>
  <keyword>Germany</keyword>
  <keyword>Palliative Treatment</keyword>
  <keyword>Adjuvant Treatment</keyword>
  <keyword>Neoadjuvant Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

